Company: BLUWU
Filing Date: 2025-02-20
Form Type: S-1
Source: 0001493152-25-007630
Chunk: 13

Company: Blue Water Acquisition Corp. III
Filing Date: 2025-02-20
Form: S-1
Chunk 13
---
 diagnostic tools and health technology solutions. Key areas of focus include:

| ● | Pharmaceutical                                                                        
 Development: We intend to seek investments in companies with promising drug pipelines 
 aimed at addressing unmet medical needs.                                              |

| ● | Medical                                                                                    
 Devices: Our strategy includes supporting the development of advanced devices that enhance 
 patient outcomes and streamline healthcare delivery.                                       |

| ● | Telemedicine:                                                                                     
 We aim to enhance healthcare accessibility through digital health platforms and remote monitoring 
 solutions.                                                                                        |

| ● | Health                                                                                  
 Tech Innovations: Our focus encompasses advancements in AI-driven diagnostics, wearable 
 health technologies, and health data analytics.                                         |

Technology The technology sector remains a critical driver of economic growth and innovation. Our investment strategy is centered on companies that are revolutionizing industries through advanced technological solutions. Key areas of interest include:

| ● | Artificial                                                                               
 Intelligence and Machine Learning: We intend to invest in AI-driven companies that offer 
 transformative solutions across multiple sectors.                                        |

| ● | Cloud                                                                                             
 Computing: Our focus includes businesses that provide scalable and efficient cloud infrastructure 
 and services.                                                                                     |

| ● | Cybersecurity:                                                                            
 We prioritize investments in companies developing cutting-edge cybersecurity solutions to 
 enhance digital security.                                                                 |

| ● | Enterprise                                                                                     
 Software Solutions: Our strategy supports software companies that enhance business efficiency, 
 productivity and decision-making.                                                              |

| 3 |

Our Founders and Management Team Our management team comprises seasoned professionals with extensive experience across the biotechnology, healthcare and technology sectors. With backgrounds in leadership positions at top 500 public companies, our team possesses a deep understanding of industry dynamics and investment strategies essential for driving success. Our management team has accumulated decades of experience with top public companies, achieving significant milestones, such as:

| ● | Leading                                                                                 
 R&D initiatives in major pharmaceutical firms, culminating in the launch of blockbuster 
 drugs.                                                                                  |

| ● | Developing                                                           
 and scaling health technology startups acquired by industry leaders. |

| ● | Managing                                                                                       
 large-scale IT projects within multinational corporations to enhance operational efficiencies. |

| ● | Spearheading                                                                             
 strategic initiatives in biotechnology firms that resulted in groundbreaking discoveries 
 and FDA approvals.                                                                       |

| ● | Successfully                                                                                  
 spinning out over 12 companies and bringing five public through reverse mergers, direct IPOs, 
 and M&A transactions.                                                                         |

See “ Management” and “ Management – Prior Experience with Blank Check Companies” for additional information about our directors and executive officers. Joseph Hernandez, our Chairman and Chief Executive Officer since inception, is an